Browse FGFR4

Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Endosome. Endoplasmic reticulum. Note=Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane.; SUBCELLULAR LOCATION: Isoform 2: Secreted.; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm
Domain PF07679 Immunoglobulin I-set domain
PF07714 Protein tyrosine kinase
Function

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.

> Gene Ontology
 
Biological Process GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006694 steroid biosynthetic process
GO:0006699 bile acid biosynthetic process
GO:0008202 steroid metabolic process
GO:0008206 bile acid metabolic process
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0008654 phospholipid biosynthetic process
GO:0010565 regulation of cellular ketone metabolic process
GO:0010715 regulation of extracellular matrix disassembly
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0016053 organic acid biosynthetic process
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019216 regulation of lipid metabolic process
GO:0019218 regulation of steroid metabolic process
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0030258 lipid modification
GO:0032844 regulation of homeostatic process
GO:0033500 carbohydrate homeostasis
GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process
GO:0042180 cellular ketone metabolic process
GO:0042593 glucose homeostasis
GO:0042632 cholesterol homeostasis
GO:0043062 extracellular structure organization
GO:0043410 positive regulation of MAPK cascade
GO:0044283 small molecule biosynthetic process
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045017 glycerolipid biosynthetic process
GO:0045862 positive regulation of proteolysis
GO:0046394 carboxylic acid biosynthetic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046777 protein autophosphorylation
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0046890 regulation of lipid biosynthetic process
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0050810 regulation of steroid biosynthetic process
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0055062 phosphate ion homeostasis
GO:0055081 anion homeostasis
GO:0055088 lipid homeostasis
GO:0055092 sterol homeostasis
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070857 regulation of bile acid biosynthetic process
GO:0071774 response to fibroblast growth factor
GO:0071897 DNA biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
GO:0072506 trivalent inorganic anion homeostasis
GO:1903053 regulation of extracellular matrix organization
GO:1904251 regulation of bile acid metabolic process
GO:2000188 regulation of cholesterol homeostasis
GO:2000278 regulation of DNA biosynthetic process
GO:2000573 positive regulation of DNA biosynthetic process
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005007 fibroblast growth factor-activated receptor activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0016303 1-phosphatidylinositol-3-kinase activity
GO:0017134 fibroblast growth factor binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0052742 phosphatidylinositol kinase activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
GO:1901681 sulfur compound binding
Cellular Component GO:0030133 transport vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-5654716: Downstream signaling of activated FGFR4
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-190322: FGFR4 ligand binding and activation
R-HSA-1839128: FGFR4 mutant receptor activation
R-HSA-5654712: FRS-mediated FGFR4 signaling
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5654733: Negative regulation of FGFR4 signaling
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-5654720: PI-3K cascade
R-HSA-109704: PI3K Cascade
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-5654228: Phospholipase C-mediated cascade; FGFR4
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-5654719: SHC-mediated cascade
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654743: Signaling by FGFR4
R-HSA-5655291: Signaling by FGFR4 in disease
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-1307965: betaKlotho-mediated ligand binding
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FGFR4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FGFR4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FGFR4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6070.255
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.6550.0674
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.150.857
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3260.549
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.220.884
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0130.57
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.4090.0174
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9880.262
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.7880.0589
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.0160.547
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.4860.523
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2220.299
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FGFR4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FGFR4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FGFR4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FGFR4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FGFR4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FGFR4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FGFR4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFGFR4
Namefibroblast growth factor receptor 4
Aliases JTK2; CD334; TKF; tyrosine kinase related to fibroblast growth factor receptor; CD antigen CD334; FGFR-4
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FGFR4 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FGFR4.
ID Name Drug Type Targets #Targets
DB00039PaliferminBiotechFGFR1, FGFR2, FGFR3, FGFR4, HSPG2, NRP16
DB01109HeparinSmall MoleculeF10, FGF1, FGF19, FGF2, FGF4, FGFR1, FGFR2, FGFR4, HGF, PF4, SELP, ......12
DB08901PonatinibSmall MoleculeABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......15
DB09078LenvatinibSmall MoleculeFGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, KIT8